Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept 24-week study of Sarilumab in active rheumatoid arthritis despite prior TNF agents
2019-003138-17Phase 4Active
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of sarilumab in rheumatoid arthritis (RA), sponsored by Cliniques universitaires Saint-Luc. Primary endpoints: Global gene expression profiles in synovial biopsies, Pathological characteristics of synovial biopsies and 1 more. Started Nov 2019; status: active.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-003138-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003138-17.